From grimoire
Manages Group B Streptococcus in pregnancy: screening at 35-37 weeks, intrapartum antibiotic prophylaxis (IAP), and neonatal sepsis prevention. Follows ACOG/CDC guidelines.
How this skill is triggered — by the user, by Claude, or both
Slash command
/grimoire:design-group-b-strep-protocolThe summary Claude sees in its skill listing — used to decide when to auto-load this skill
Screen for GBS at 35–37 weeks and execute the intrapartum antibiotic prevention protocol.
Screen for GBS at 35–37 weeks and execute the intrapartum antibiotic prevention protocol.
Adopted by: ACOG, CDC, AAP — universal GBS screening and intrapartum antibiotic prophylaxis (IAP) is the standard of care in the US, UK, Canada, and Australia. Impact: IAP reduced early-onset neonatal GBS disease by 80% from 1990 to 2020 (CDC surveillance data). Without IAP, GBS-positive mothers have a 1 in 200 chance of neonatal sepsis; with IAP, risk falls to <1 in 4,000 (ACOG 2020). Why best: GBS colonization is transient and harmless to the mother but causes severe sepsis, meningitis, and death in neonates. Screening + IAP is the most effective intervention.
GBS positive at 36 weeks: Document result, give patient card to carry, tell patient to notify L&D of GBS+ status on arrival; receive Pen G on admission, before any other interventions. Unknown GBS status, water broke at 39 weeks: Go directly to hospital; receive IAP because ROM ≥18 hours threshold may be crossed.
Health Disclaimer: GBS management requires coordination between prenatal care provider and labor and delivery team. Patients should understand their GBS status before 37 weeks and communicate it on arrival to hospital.
npx claudepluginhub jeffreytse/grimoire --plugin grimoireCreates a gestational-age–based prenatal genetic screening plan: NIPT, NT ultrasound, serum screens, quad screen, CVS, amniocentesis, GBS screening.
Searches 12+ authoritative clinical guideline sources (NICE, WHO, NCCN, AHA, ADA, SIGN, USPSTF, IDSA, ESMO, ESC, EASL) for evidence-graded treatment recommendations, dosing protocols, and screening guidance with source prioritization.
Generates clinical trial protocols for medical devices or drugs, including research-only and full protocol modes with waypoint-based architecture.